Kanada - englanti - Health Canada

teva canada limited - fluvastatin (fluvastatin sodium) - capsule - 20mg - fluvastatin (fluvastatin sodium) 20mg - hmg-coa reductase inhibitors

Kanada - englanti - Health Canada

teva canada limited - fluvastatin (fluvastatin sodium) - capsule - 40mg - fluvastatin (fluvastatin sodium) 40mg - hmg-coa reductase inhibitors

Kanada - englanti - Health Canada

sandoz canada incorporated - fluvastatin (fluvastatin sodium) - capsule - 20mg - fluvastatin (fluvastatin sodium) 20mg - hmg-coa reductase inhibitors

Kanada - englanti - Health Canada

sandoz canada incorporated - fluvastatin (fluvastatin sodium) - capsule - 40mg - fluvastatin (fluvastatin sodium) 40mg - hmg-coa reductase inhibitors

Kanada - englanti - Health Canada

sandoz canada incorporated - fluvastatin (fluvastatin sodium) - tablet (extended-release) - 80mg - fluvastatin (fluvastatin sodium) 80mg - hmg-coa reductase inhibitors

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - anastrozole - film coated tablet - 1 milligram - aromatase inhibitors

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

synthon bv - anastrozole - film-coated tablet - 1 milligram(s) - aromatase inhibitors; anastrozole

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

synthon bv - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Euroopan unioni - englanti - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - pemetrexed - carcinoma, non-small-cell lung; mesothelioma - folic acid analogues, antineoplastic agents - malignant pleural mesothelioma pemetrexed medac in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer pemetrexed medac in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed medac is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed medac is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

aspire pharma limited - bortezomib - powder for solution for injection - 1 milligram(s) - other antineoplastic agents; bortezomib